AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BETWEENCollaboration and License Agreement • June 20th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations
This Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of [ ] (the “Execution Date”) by and between AnHeart Therapeutics (Hangzhou) Co., Ltd. (葆元生物医药科技（杭州）有限公司), a Chinese corporation having an office and place of business at Room 401-19, Building 6, Yinhai Science and Technology Innovation Center, No. 501 Fucheng Road, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province, China (“AnHeart”); and Innovent Biologics (Suzhou) Co. Ltd., (信达生物制药（苏州）有限公司), a Chinese corporation having an office and place of business at 168 Dongping Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province, China (“Innovent”). AnHeart and Innovent are each referred to herein by name, individually as a “Party”, or collectively as the “Parties”.
COLLABORATION AND LICENSE AGREEMENT BETWEEN ANHEART THERAPEUTICS (HANGZHOU) CO., LTD. AND INNOVENT BIOLOGICS (SUZHOU) CO. LTD., May 31, 2021Collaboration and License Agreement • June 20th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations
This Collaboration and License Agreement (this “Agreement”), dated May 31, 2021 (the “Effective Date”), is entered into by and between: AnHeart Therapeutics (Hangzhou) Co., Ltd.(葆元生物医药科技（杭州）有限公司), a Chinese corporation having an office and place of business at Room 423, Building No. 1, Heda Pharma Town, No. 291 Fucheng Road, Xiasha, Qiantangxin District, Hangzhou, Zhejiang 310018 China (“AnHeart”); and Innovent Biologics (Suzhou) Co. Ltd., (信达生物制药（苏州）有限公司) a Chinese corporation having an office and place of business at 168 Dongping Street, Suzhou Industrial Park, Suzhou Jiangsu 215123, China (“Innovent”). AnHeart and Innovent are each referred to herein by name, individually as a “Party”, or collectively as the “Parties”.
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • June 20th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations
This License and Commercialization Agreement (this “Agreement”), dated October 27th, 2023 (the “Effective Date”), is entered into by and between: AnHeart Therapeutics Inc., a Delaware corporation having its office and place of business at 777 3rd avenue, New York, NY 10017, USA (“AnHeart”); and Nippon Kayaku Co., Ltd., a Japanese corporation having its office and place of business at 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-0005, Japan (“NK”). AnHeart and NK are each referred to herein by name, individually as a “Party”, or collectively as the “Parties”.
